Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase.

Richard M Bergenstal1, William V Tamborlane, Andrew Ahmann

  • 1International Diabetes Center at Park Nicollet, Minneapolis, Minnesota, USA. richard.bergenstal@parknicollet.com

Diabetes Care
|September 22, 2011
PubMed
Summary

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Detectable C-Peptide and Diabetic Ketoacidosis Risk in Type 1 Diabetes.

Diabetes care·2026
Same author

A joint model for a longitudinal outcome and a progressive multistate model under a mixed observation scheme.

Statistical methods in medical research·2026
Same author

Genetic Risk Factors for Kidney Function in Individuals with Type 1 Diabetes.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Intrapartum and Early Postpartum Use of Automated Insulin Delivery in Type 1 Diabetes: A Prespecified Analysis of the CIRCUIT Randomized Controlled Trial.

Diabetes care·2026
Same author

A Patient-Clinician Co-Designed Infographic for Diabetic Ketoacidosis Education in Type 1 Diabetes.

Canadian journal of diabetes·2026
Same author

Clinical Diabetic Peripheral Neuropathy: Can It Be Reversed? Arguments for and Against From a NEUROdiab Debate.

Journal of the peripheral nervous system : JPNS·2026

Switching to sensor-augmented pump (SAP) therapy from multiple daily injections (MDI) rapidly lowers A1C. Continuous SAP use maintains these glycemic benefits for at least 18 months in people with diabetes.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Medical Devices

Background:

  • Optimized multiple daily injection (MDI) therapy is a standard for diabetes management.
  • Sensor-augmented pump (SAP) therapy integrates continuous glucose monitoring with insulin pump technology.
  • Understanding the transition and long-term effects of switching to SAP is crucial for diabetes care optimization.

Purpose of the Study:

  • To evaluate the impact of transitioning from optimized MDI to SAP therapy over 6 months.
  • To assess the sustained glycemic benefits of SAP therapy over 18 months.
  • To determine the safety and efficacy of SAP therapy in a real-world clinical setting.

Main Methods:

  • A 6-month, single-crossover design was employed as part of the STAR 3 study.

Related Experiment Videos

  • 420 participants who completed a 1-year randomized trial were included.
  • The primary outcome measured was the change in glycated hemoglobin A1C (HbA1C) levels in the crossover group.

    • Main Results:

    • Initial A1C levels were lower in the group continuously using SAP compared to the crossover group (7.4% vs. 8.0%).
    • Participants switching to SAP showed a significant A1C reduction to 7.6% within 3 months (P < 0.001).
    • This A1C decrease was significant and sustained in both adult and pediatric populations (P < 0.05).

    Conclusions:

    • Transitioning from optimized MDI to SAP therapy facilitates rapid and safe reductions in A1C.
    • The glycemic improvements achieved with SAP therapy are maintained for at least 18 months.
    • SAP therapy represents an effective strategy for enhancing glycemic control in individuals with diabetes.